Opinion statement
Many patients with epilepsy are on lifelong therapy with antiepileptic drugs (AEDs), and AEDs are used for other conditions such as mood stabilization and headache prophylaxis. These drugs have high potential for clinically significant interaction with nonepilepsy drugs. Interactions occur largely through altered pharmacokinetics. One drug may increase the hepatic clearance of another, leading to attenuated efficacy of the affected drug. Alternatively, inhibition of liver metabolism by one drug can cause acute toxicity by reducing clearance of another drug. To identify potential drug interactions before they lead to toxicity or therapy failure, the treating clinician should combine knowledge of the patient’s overall history with a general knowledge of comorbid conditions in which significant interactions involving AEDs are most likely to occur. Treatments susceptible to interactions include anticoagulants, antiarrhythmics, antibiotics, antiretroviral drugs, immunosuppressives, antineoplastics, and contraceptives. Therefore, it is important to obtain periodically a thorough history of medical problems, use of medications or herbal remedies, and adverse effects of medications. Physicians managing epilepsy patients should also strive to avoid potential drug interactions by favoring low-interaction AEDs in patients taking many other types of drugs. There is quite a large degree of patient heterogeneity in the extent of any given interaction between an AED and another drug. Indeed, some groups of patients may have different susceptibilities to such interactions because of genetic and environmental influences on drug metabolism. Effective treatment with AEDs should include attention to drug interactions.
Similar content being viewed by others
References and Recommended Reading
Dickson M, Bramley TJ, Kozma C, et al.: Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients. Am J Health Syst Pharm 2008, 65:1720–1726.
Majkowski J, Patsalos PN: Interactions between antiepileptic and non-antiepileptic drugs. In Antiepileptic Drugs: Combination Therapy and Interactions. Edited by Majkowski J, Bourgeois BFD, Patsalos PN, Mattson RH. New York: Cambridge University Press; 2005:139–176.
Patsalos PN, Perucca E: Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003, 2:473–481.
Perucca E: Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharm 2006, 61:246–255.
Pollard JR, Delanty N: Antiepileptic drug interactions. Continuum: Epilepsy 2007, 13:91–105.
Patsalos PN, Perucca E: Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003, 2:347–356.
French JA, Gidal BE: Antiepileptic drug interactions. Epilepsia 2000, 41(Suppl 8):S30–S36.
Krämer G, Tettenborn B, Klosterskov Jensen P, et al.: Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992, 33:1145–1148.
Nolan PE Jr, Marcus FI, Karol MD, et al.: Effect of phenytoin on the clinical pharmacokinetics of amiodarone. J Clin Pharmacol 1990, 30:1112–1119.
Macphee GJ, McInnes GT, Thompson GG, Brodie MJ: Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1986, 1(8483):700–703.
Shorvon SD, Tallis RC, Wallace HK: Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry 2002, 72:114–115.
Harden CL, Leppik I: Optimizing therapy of seizures in women who use oral contraceptives. Neurology 2006, 67:S56–S58.
Schwenkhgaen AM, Stodieck SR: Which contraception for women with epilepsy? Seizure 2008, 17:145–150.
Erkkola R, Landgren BM: Role of progestins in contraception. Acta Obset Gynecol Scand 2005, 84:207–216.
Coulam CB, Annegers JF: Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979, 20:519–525.
Reimers A, Helde G, Brodtkorb E: Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005, 46:1414–1417.
Herzog AG, Farina EL, Blum AS: Serum valproate levels with oral contraceptive use. Epilepsia 2005, 46:970–971.
Lacerda G, Krummel T, Sabourdy C, et al.: Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006, 67(12 Suppl 4):S28–S33.
Buur-Rasmussen B, Brøren K: Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol 1999, 9:453–459.
Koch-Stoecker S: Antipsychotic drugs and epilepsy: indications and treatment guidelines. Epilepsia 2002, 43(Suppl 2):19–24.
Desai J: Perspectives on interactions between antiepileptic drugs (AEDs) and antimicrobial agents. Epilepsia 2008, 49(Suppl 6):47–49.
Kay L, Kampmann JP, Svendsen TL, et al.: Influence of rifampin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 1985, 20:323–326.
Satishchandra P, Sinha S: Seizures in HIV-seropositive individuals. NIMHANS experience and review. Epilepsia 2008, 49(Suppl 6):33–41.
Bhigjee AI, Rosemberg S: Optimizing therapy of seizures in patients with HIV and cysticercosis. Neurology 2006, 67(12 Suppl 4):S19–S22.
Bittencourt PR, Gracia CM, Martins R, et al.: Phenytoin and carbamazepine decreased oral bioavailability of praziquantel. Neurology 1992, 42(3 Pt 1):492–496.
Mori H, Takahashi K, Mizutani T: Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev 2007, 39:647–657.
Peebles CT, McAuley JW, Roach J, et al.: Alternative medicine use by patients with epilepsy. Epilepsy Behav 2000, 1:74–77.
Samuels N, Finkelstein Y, Singer SR, Oberbaum M.: Herbal medicine and epilepsy: proconvulsive effects and interactions with antiepileptic drugs. Epilepsia 2008, 49:373–380.
Vecht CJ, van Breemen M: Optimizing therapy of seizures in patients with brain tumors. Neurology 2006, 67:S10–S13.
Oberndorfer S, Piribauer M, Marosi C, et al.: P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005, 72:255–260
Relling MV, Pui CH, Sandlund JT, et al.: Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000, 356:285–290.
Chabolla DR, Wszolek ZK: Pharmacologic management of seizures in organ transplant. Neurology 2006, 67(12 Suppl 4):S34–S38.
Leppik IE: Treatment of epilepsy in the elderly. Curr Treat Options Neurol 2008, 10:239–245.
Foldavary-Shaefer N, Wyllie E: Neuropharmacology of the antiepileptic drugs. In Textbook of Clinical Neurology, edn 2. Edited by Goetz CG. New York: Saunders; 2003:1177–1181.
Levy RH, Bourgeois BFD, Hachad H: Drug-drug interactions. In Epilepsy: A Comprehensive Textbook. Edited by Engel J Jr, Pedley TA. Philadelphia: Lippincott Williams & Wilkins; 2008:1235–1248.
Wright JM: Drug interactions. In Melmon and Morrelli’s Clinical Pharmacology: Basic Principles in Therapeutics, edn 4. Edited by Carruthers SG, Hoffman BB, Melmon KL, Nierenberg DW. New York: McGraw-Hill; 2000:1257–1266.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mani, R., Pollard, J.R. Antiepileptic drugs and other medications: What interactions may arise?. Curr Treat Options Neurol 11, 253–261 (2009). https://doi.org/10.1007/s11940-009-0029-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-009-0029-1